167 related articles for article (PubMed ID: 30648199)
1. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.
Sasada S; Masumoto N; Suzuki E; Sueoka S; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):831-837. PubMed ID: 30648199
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
3. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
[No Abstract] [Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
[TBL] [Abstract][Full Text] [Related]
6. Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer.
Ikejiri H; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Breast; 2022 Oct; 65():98-103. PubMed ID: 35921799
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
[TBL] [Abstract][Full Text] [Related]
8. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
9. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
10. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
Choi WH; Yoo IR; O JH; Kim SH; Chung SK
Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
[TBL] [Abstract][Full Text] [Related]
11. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of
Song BI; Kim HW; Won KS
Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
[TBL] [Abstract][Full Text] [Related]
14. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
Kim JY; Lee SH; Kim S; Kang T; Bae YT
Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
16. Combination of breast imaging parameters obtained from
Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
[TBL] [Abstract][Full Text] [Related]
17. Metabolic changes in breast cancer on dual-time-point
Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
[TBL] [Abstract][Full Text] [Related]
18. Utility of
Yamagishi Y; Yamasaki T; Ishida J; Moriya T; Einama T; Koiwai T; Fukumura-Koga M; Kono T; Hayashi K; Ueno H; Yamamoto J; Tsuda H
Ann Surg Oncol; 2020 Aug; 27(8):2698-2710. PubMed ID: 32124121
[TBL] [Abstract][Full Text] [Related]
19. Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers of breast cancer.
Kaida H; Azuma K; Toh U; Kawahara A; Sadashima E; Hattori S; Akiba J; Tahara N; Rominger A; Ishii K; Murakami T; Ishibashi M
Hell J Nucl Med; 2018; 21(1):35-42. PubMed ID: 29550845
[TBL] [Abstract][Full Text] [Related]
20. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
